Reta (10mg)

Retatrutide (10mg) - Advanced Triple Receptor Agonist Research Compound Molecular Profile: Retatrutide is a 39-amino acid synthetic peptide with molecular weight ~4,600 Da (CAS 2381089-83-2). Features GIP peptide backbone conjugated to C20 fatty diacid moiety with Aib modifications for DPP-4 resistance and extended half-life. Triple Agonist Mechanism: Simultaneously activates three class B1 GPCRs - GIPR (EC₅₀: 0.0643 nM), GLP-1R (EC₅₀: 0.775 nM), and GCGR (EC₅₀: 5.79 nM). This "triple G" mechanism enables synergistic metabolic pathway investigation through combined incretin and glucagon receptor signaling. Thermogenesis & Energy Expenditure: GCGR agonism component increases metabolic rate, promotes mitochondrial biogenesis, activates brown adipose tissue, and enhances hepatic fatty acid oxidation - providing unique research applications for energy expenditure mechanisms. Product Specifications: - Purity: ≥95% by HPLC - Appearance: White to off-white lyophilized powder - Solubility: Soluble in water, PBS, physiological buffers - Storage: -20°C or -80°C long-term; 2-8°C short-term - Quality Control: Identity confirmed by MS, purity by HPLC, CoA available Laboratory Use Only Disclaimer: FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. This research-grade compound is intended exclusively for laboratory investigations by qualified professionals. Not approved for clinical, diagnostic, or therapeutic applications. Handle with appropriate PPE in controlled laboratory environments. IACUC/IRB approval required for applicable studies. Purchaser assumes all liability for proper use and regulatory compliance.